CAPR
CAPRICOR THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$8.92
+8.25%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$8.16
From 52W high−74.76%
Volume6.35M
Market cap$518.60M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$8.16
From 52W high
−74.76%
Volume
6.35M
Market cap
$518.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
60.4
MomentumView details →
1D Return
+8.25%
YTD Return
−70.82%
SummaryUpdated Jun 1, 2026
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company founded in 2005 and headquartered in San Diego, California. The company went public in 2007 and focuses on developing transformative cell and exosome-based therapeutics for treating various diseases and disorders. Capricor is primarily known for its lead candidate <b>deramiocel</b> (formerly CAP-1002), an allogeneic cardiac-derived cell therapy that has completed Phase III clinical trials for treating late-stage Duchenne muscular dystrophy (DMD). The company has submitted a Biologics License Application (BLA) to the FDA for deramiocel, with a priority review PDUFA date of August 31, 2025.
Similar companies
Latest newsMore news →
CAPRICOR THERAPEUTICS, INC. announced that it will release its third-quarter 2026 financial results after the market close on November 10, 2026.1d agoCapricor Therapeutics presented new 24-month data from the HOPE-3 open-label extension study showing that Deramiocel continued to slow upper limb function decline in patients with Duchenne muscular dystrophy, at the 2026 World Muscle Society meeting in Hiroshima, Japan.30d agoCapricor Therapeutics stock closed Tuesday at $8.57, down 1.61%, with the daily trend bearish and price below its EMA20, EMA50 and EMA200.36d ago